Two FTSE 250 growth stocks I’d buy before it’s too late

These two FTSE 250 (INDEXFTSE:MCX) companies could be worth buying right now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In the last year, the FTSE 100 has outperformed the FTSE 250 by around 8%. Much of this is because of the former’s focus on international companies. They have generally benefitted from rising valuations as sterling has weakened, while many mid-cap shares are more UK-focused. Since Brexit means economic uncertainty, it is unsurprising that large-cap shares have outperformed their smaller peers.

This means there may be bargains on offer within the FTSE 250. Here are two growth stocks which may not remain at relatively cheap prices indefinitely.

Healthcare potential

Demand for healthcare products and services is likely to rise rapidly in future years. The world’s population is not only increasing, it is also ageing. Therefore, investor sentiment towards the healthcare sector could improve over the long run. And since it is generally less positively correlated to the wider economy than most sectors, it could also provide a degree of stability and diversification in case the outlook for the global economy deteriorates.

Within the healthcare sector, interventional medicine specialist BTG (LSE: BTG) could deliver high returns. It is forecast to record a rise in its bottom line of 49% next year, followed by growth of 15% in the following year. Despite this, it trades on a price-to-earnings (P/E) ratio of 27, which puts it on a price-to-earnings growth (PEG) ratio of just 0.8. This indicates that it offers a sufficiently wide margin of safety to merit investment at the present time.

Certainly, BTG’s income appeal is non-existent right now, since it pays no dividend. However, as the company matures it is likely to begin to pay out a proportion of profit to shareholders. This could act as an additional catalyst on its shares and signal confidence in its long-term outlook.

Property potential

Rises in tuition fees do not appear to have reduced demand for university places. In 2015, it reached its highest recorded figure in history, with 532,300 people entering higher education in the UK. Given the pressure on housing in the general UK population, it is unsurprising that the provision of student accommodation has proved to be a profitable endeavour for companies such as Unite Group (LSE: UTG).

It has recorded double-digit growth in each of the last five years. Not only does this mark it out as an impressive growth play, it also signals that the company offers defensive characteristics. They could prove useful if Brexit equates to even greater uncertainty among investors.

Looking ahead, Unite is expected to record a rise in its bottom line of 9% this year and 16% next year. Its shares may trade on a P/E ratio of 20.7, but their PEG ratio of just 1.7 indicates that they offer good value when their relatively low risk profile is taken into account. Furthermore, Unite currently yields 3.5% from a dividend which is covered 1.4 times by profit. Therefore, as well as being an attractive growth stock, it continues to offer above-average income prospects.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens has no position in any shares mentioned. The Motley Fool UK has recommended BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Now 70p, is £1 the next stop for the Vodafone share price?

The Vodafone share price is back to 70p, but it's a long way short of the 97p it hit in…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

If I’d put £5,000 in Nvidia stock at the start of 2024, here’s what I’d have now

Nvidia stock was a massive winner in 2023 as the AI chipmaker’s profits surged across the year. How has it…

Read more »

Light bulb with growing tree.
Investing Articles

3 top investment trusts that ‘green’ up my Stocks and Shares ISA

I’ll be buying more of these investment trusts for my Stocks and Shares ISA given the sustainable and stable returns…

Read more »

Investing Articles

8.6% or 7.2%? Does the Legal & General or Aviva dividend look better?

The Aviva dividend tempts our writer. But so does the payout from Legal & General. Here he explains why he'd…

Read more »

a couple embrace in front of their new home
Investing Articles

Are Persimmon shares a bargain hiding in plain sight?

Persimmon shares have struggled in 2024, so far. But today's trading update suggests sentiment in the housing market's already improving.

Read more »

Market Movers

Here’s why the Unilever share price is soaring after Q1 earnings

Stephen Wright isn’t surprised to see the Unilever share price rising as the company’s Q1 results show it’s executing on…

Read more »

Investing Articles

Barclays’ share price jumps 5% on Q1 news. Will it soon be too late to buy?

The Barclays share price has been having a great time this year, as a solid Q1 gives it another boost.…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

The AstraZeneca share price lifts 5% on a top-and-bottom earnings beat

The AstraZeneca share price reached £120 today and helped push the FTSE 100 higher. Would I still buy this flying…

Read more »